Skip to main content
Premium Trial:

Request an Annual Quote

CollabRx, Sengenics Partner on Cancer Diagnostics

NEW YORK (GenomeWeb News) – CollabRx today announced a deal with Sengenics to incorporate each other's products into molecular diagnostics tests and reports aimed at cancer.

Under the terms of the agreement, Sengenics will integrate CollabRx's interpretive content resources into its cancer exome sequencing tests and reports. The combined products are being designed "to seamlessly pair test results with clinically actionable and dynamically updated knowledge on the clinical impact of specific tumor genetic profiles and associated therapeutic strategies, such as drugs and clinical trials," CollabRx said.

The San Francisco-based data analytics firm added that it will provide content in a software-as-a-service-based business model.

The deal, CollabRx said, extends its presence into three continents: North America, Europe, and Asia. Financial and other terms of the agreement were not disclosed.

Today's announcement follows a test and medical information development partnership between CollabRx and OncoDNA that was announced last week.

Based in Kuala Lumpur, Malaysia, Sengenics offers genomics- and proteomics-based diagnostics.

"Our joint solution's ability to provide insights from CollabRx's clinical practitioner network represents critical and timely value to physicians when they are interpreting test results," Arif Anwar, executive director of Sengenics, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.